Document is current
Any future updates will be listed below
-
Authors
Madan, Ajay http://orcid.org/0000-0002-8563-2546
Markison, Stacy
Betz, Stephen F.
Krasner, Alan
Luo, Rosa
Jochelson, Theresa
Lickliter, Jason
Struthers, R. Scott
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03276858 at ClinicalTrials.govDocuments that mention this clinical trial
Paltusotine, a novel oral once-daily nonpeptide SST2 receptor agonist, suppresses GH and IGF-1 in healthy volunteers
https://doi.org/10.1007/s11102-021-01201-z
-
Funding
Funding for this research was provided by:
Crinetics Pharmaceuticals, Inc
National Institute of Health (Innovation Research grant R44DK088501)
- License Information
-
More Information
Article History
Accepted: 8 December 2021
First Online: 9 January 2022
Declarations
:
: Ajay Madan, Stacy Markison, Stephen F. Betz, Alan Krasner, Rosa Luo, and R. Scott Struthe are employees of Crinetics Pharmaceuticals, Inc. Theresa Jochelson is a consultant for Crinetics Pharmaceuticals, Inc. Jason Lickliter is an employee of Nucleus Network.
: The trial was conducted in accordance with Good Clinical Practice and the principles in the Declaration of Helsinki. The study was approved by the Alfred Hospital Ethics Committee (Melbourne, Australia).
: Participants provided written informed consent before any study procedures.
: All the authors vouch for the completeness and accuracy of the data and the analyses and for the fidelity of the trial to the protocol. All authors approved the final manuscript for submission. The authors affirm that participants provided signed informed consent regarding publication of their data.
